Page 109 - Human Use News Today

Phase III VISION trial showed Pluvicto plus best standard of care significantly improved survival for patients with pre-treated PSMA-positive mCRPC1 Approximately 473,000 prostate cancer cases and

CHMP opinion based on pivotal ICONIC study with more than five years of data demonstrating durable and clinically meaningful improvements in cholestatic pruritus and serum bile acids for patients with

TAK-003 Recommended for the Prevention of Dengue Disease Caused by Any Dengue Virus Serotype in Individuals Four Years of Age and Older in the EU and in Dengue-Endemic Countries Participating in

SHELTON, CT / ACCESSWIRE / October 14, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2022

BASEL (dpa-AFX) - Novartis Inc. (NVS) announced Friday that it received positive opinion from the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency for Pluvicto.

CHMP positive opinion is based on evidence from the EFFISAYIL 1 trial, the largest clinical trial in patients with generalized pustular psoriasis (GPP) flares1 GPP is a rare and potentially

Recommendation based on a Phase 3 Libtayo trial that was first and only to demonstrate significantly improved survival compared to chemotherapy in...

14.10.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing innovative and affordable oncology medicines to improve treatment outcomes and access for patients worldwide, today announced that the Committee ... Seite 1

(RTTNews) - Mirum Pharmaceuticals, Inc. (MIRM) announced Friday that the European Committee for Medicinal Products for Human Use or CHMP has adopt...

(RTTNews) - Atara Biotherapeutics, Inc. (ATRA) and Pierre Fabre announced the Committee for Medicinal Products for Human Use of the European Medic...